

ASX Release

Anatara begins field trials of Detach™ to support registration

Key points:

- Final product registration trials commence
- First piglets dosed with Detach™ in field trial
- Production of Detach™ at commercial scale complete
- Trial is designed to support the reduction of the use of antibiotics in livestock
- Trial is designed to support the use of Detach™ in humans

BRISBANE, 19th December 2014: Anatara Lifesciences (ASX: ANR) is pleased to announce it has begun the first pivotal field trial of its lead product Detach™, a non-antibiotic, natural product to prevent and treat diarrhoea in piglets.

The field trials are being conducted in commercial piggeries throughout Australia and will support Anatara's application to register Detach™ for sale in Australia with the Australian Pesticides and Veterinary Medicines Authority (APVMA).

A minimum of 400 piglets have been enrolled in this first study with results expected in the first quarter of 2015. The first piglets have been dosed with Detach™ in a placebo controlled, parallel group, randomised and blinded study.

The trials will investigate the ability of Detach™ to reduce the incidence, severity and duration of diarrhoea, otherwise known as scour, compared to placebo. Scour will be assessed by a scour score that measures the incidence and severity of scour as well as piglet clinical condition. Other trial endpoints include increases in average daily weight gain as well as the reduction in antibiotic treatments.

The trials have commenced using Detach™ manufactured under the code of good manufacturing practice (cGMP), and just under 500,000 doses at commercial scale has been produced in line with registration requirements of the APVMA.

Anatara Chief Scientific Officer Dr Tracey Mynott said: "Detach™ has already been shown to be effective in preventing scour in piglets in earlier Australian and international field trials. Assuming these new trial data support the



existing data, Anatara expects to submit its registration application for Detach™ in pigs with the APVMA in mid-2015.”

There is now an urgent need to reduce the use of antibiotics in humans and animals because of the emergence of antibiotic resistance in bacteria. Antimicrobial resistance is a serious worldwide problem for both humans and animals, and is an issue that governments around the world are grappling with.

“We are excited that Detach™ can potentially make a significant contribution to reducing reliance upon the use of antibiotics for the control of diarrhoea in farm animals,” Dr Mynott said.

“Since listing in October 2014 the Anatara team has worked diligently to bring Detach™ to this significant milestone as we progress with our plans to launch this product initially on the Australian market, followed by registration in other important international markets,” Chairman Dr Mel Bridges said.

Anatara expects Detach™ to be on sale in mid-2016 based on the current pace of progress and that the results support existing data.

For more information please contact:

General inquiries

Mel Bridges
Chairman
+61 413 051 600
melbridges@parmacorp.com

Media inquiries

Gavin Lower
Buchan Consulting
+61 3 8866 1215
glower@buchanwe.com.au

About Anatara Lifesciences

Anatara Lifesciences is developing therapeutics for gastrointestinal diseases in production animals and humans. Its lead product Detach™ is a natural plant based product that will help address global concerns around the overuse of antibiotics in production animals that is contributing to the rise of so-called “super bugs” that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies.